NCT06908096View on ClinicalTrials.gov

Epstein-Barr Virus (EBV) gH/gL/gp42-Ferritin Nanoparticle Vaccine With or Without gp350-Ferritin in Healthy Adults With or Without EBV Infection

PHASE1RecruitingINTERVENTIONAL
Enrollment

750

Participants

Timeline

Start Date

May 29, 2025

Primary Completion Date

October 1, 2027

Study Completion Date

October 1, 2028

Conditions
EBVEpstein-Barr Virus InfectionInfectious MononucleosisMono
Interventions
BIOLOGICAL

EBV gp350-ferritin vaccine with ALFQ adjuvant

The adjuvanted gH/gL/gp42-ferritin nanoparticle vaccine is given with gp350-ferritin intramuscularly into the deltoid muscle at 0, 1, and 4 months.

BIOLOGICAL

EBV gH/gL/gp42-ferritin nanoparticle vaccine with ALFQ adjuvant

The adjuvanted gH/gL/gp42-ferritin nanoparticle vaccine is given with gp350-ferritin intramuscularly into the deltoid muscle at 0, 1, and 4 months.

Trial Locations (1)

20892

RECRUITING

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH